Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cann in a research report issued on Thursday. They currently have a $27.00 price target on the stock. Cann’s target price indicates a potential upside of 61.68% from the company’s current price.
KURA has been the subject of several other research reports. BidaskClub downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd. ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Wedbush started coverage on shares of Kura Oncology in a research report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Oppenheimer set a $18.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Kura Oncology presently has a consensus rating of “Buy” and a consensus price target of $22.00.
Shares of KURA stock opened at $16.70 on Thursday. The company has a market cap of $612.04, a PE ratio of -10.99 and a beta of 4.21. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 9.44.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). sell-side analysts expect that Kura Oncology will post -1.43 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC acquired a new stake in Kura Oncology in the 4th quarter valued at $155,000. Millennium Management LLC grew its position in Kura Oncology by 35.7% in the 4th quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock valued at $4,650,000 after purchasing an additional 79,989 shares during the period. Nexthera Capital LP grew its position in Kura Oncology by 72.3% in the 4th quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock valued at $6,817,000 after purchasing an additional 187,034 shares during the period. Teachers Advisors LLC lifted its stake in Kura Oncology by 52.6% during the 4th quarter. Teachers Advisors LLC now owns 37,866 shares of the company’s stock valued at $579,000 after acquiring an additional 13,050 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Kura Oncology by 48.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 29,222 shares of the company’s stock valued at $447,000 after acquiring an additional 9,590 shares in the last quarter. 58.56% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Kura Oncology (KURA) Stock Rating Reaffirmed by Cann” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/kura-oncology-kura-stock-rating-reaffirmed-by-cann.html.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.